Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PK/PD study of subcutaneous mepolizumab in children 6–11 years with severe eosinophilic asthma
2014-002666-76Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mepolizumab in eosinophilic asthma (EA), sponsored by GSK. Primary endpoints: Pharmacokinetic endpoints (Part A) and Pharmacodynamic endpoints (Part A). Started Jul 2015; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2014-002666-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002666-76.